Your trusted source for investing success

Tag: disease

Precipio in Strategic Partnership Discussions for Proprietary Cytogenetics Media IV-Cell

Specialty diagnostics company Precipio (NASDAQ:PRPO), announced today it is in active licensing discussions with several potential partners regarding IV-Cell, Precipio’s proprietary cytogenetics media.
As quoted in the press release:

Cytogenetics media is used to culture cells to mimic development of malignant cells in the body, and identify chromosomal abnormalities that may be causing cancer.

Medigus and HC Marbella International Hospital Announce First MUSE Procedure for GERD Treatment in Spain

Medigus (NASDAQ:MDGS) (TASE:MDGS), a medical device company developing minimally invasive endosurgical tools and an innovator in direct visualization technology, along with High Care Marbella International Hospital, today announced the completion of the first MUSE procedure in Spain. The procedure was performed by Dr. Victor Aguilar at HC Marbella International Hospital.

Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita

Ultragenyx Pharmaceutical (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co. Ltd (Kyowa Hakko Kirin), and Kyowa Kirin International PLC (Kyowa Kirin International) today announced that the U.S. Food and Drug Administration (FDA) has approved Crysvita® (burosumab-twza) for the

Medtronic Expands Focus on Interventional Oncology with Its U.S. Launch of OptiSphere Embolization Spheres

Medtronic (NYSE: MDT) announced its U.S. launch of OptiSphere embolization spheres, a resorbable embolic platform designed for embolization of hypervascular tumors. OptiSphere offers patients an alternative treatment option, a resorbable embolic, with comparable results to a permanent embolic.

As quoted in the press release:
Hypervascular tumors can present as malignant or benign

Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR

Akcea Therapeutics (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals and Ionis Pharmaceuticals (NASDAQ:IONS) announced the two companies have completed a previously announced transaction licensing the exclusive, worldwide rights from Ionis to Akcea for inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx.

As quoted in the press release:
Inotersen is under regulatory review in the U.S. and EU

Biomerica Announces Third Quarter Financial Results

Biomerica (Nasdaq:BMRA) today reported net sales of $4,433,785 for the nine months ending February 28, 2018, compared to $4,342,247 for the period ended February 28, 2017. Sales for the three months ending February 28, 2018 were $1,375,666 compared to $1,499,930 for the period ended February 28, 2017.

As quoted in the

Shire: FDA APPROVES VONVENDI

Shire (LSE: SHP, NASDAQ: SHPG), the global  biotechnology leader in rare disease, today announced the U.S. Food and Drug Administration (FDA) has approved VONVENDI [von Willebrand factor (recombinant)], a recombinant von Willebrand factor (rVWF) treatment for perioperative management of bleeding in adults (age 18 and older) with von Willebrand disease

VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients

VBI Vaccines (Nasdaq:VBIV) a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that, upon review of all safety data from the fully enrolled, low-dose patient cohort of the ongoing Phase 1/2a clinical study of VBI-1901 in recurrent Glioblastoma (GBM), the independent Data and Safety Monitoring Board

Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX®2-73 in Parkinson’s Disease Dementia

Anavex Life Sciences (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that the Company is planning to initiate a Phase 2 clinical trial of lead candidate

Apellis Pharmaceuticals Announces Proposed Offering of Common Stock

Apellis Pharmaceuticals (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares are being offered by

New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine’s Proprietary Delivery Platform

Immunovaccine (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it presented new research on its T-cell activating platform at the American Association for Cancer Research (AACR) Annual Meeting 2018.
As quoted in the press release:

In collaboration with Incyte Corporation, researchers presented a poster supporting the enhanced anti-cancer immune responses from

BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer

BeiGene (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that preliminary clinical data from an ongoing Phase 1 trial of its investigational PARP inhibitor pamiparib in Chinese patients with locally advanced or metastatic high-grade non-mucinous

Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting

Leap Therapeutics (NASDAQ:LPTX) presented nonclinical and clinical data on DKN-01, Leap’s anti-DKK1 monoclonal antibody, at the American Association for Cancer Research (AACR) 2018 Annual Meeting. The presentation highlighted the immunomodulatory activity of DKN-01 in nonclinical experiments and preliminary results from the dose escalation phase of the clinical study evaluating DKN-01 in

Celldex’s METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint

Celldex Therapeutics (NASDAQ:CLDX) reported that the Company’s randomized, Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda® (capecitabine) in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint, progression-free survival (PFS) as assessed by an independent, central reading of patient scans (Hazard ratio =

G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing G1T38, its oral CDK4/6 inhibitor, in combination with Tagrisso® (osimertinib) in people with EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC). AstraZeneca (LON: AZN) is providing Tagrisso for this trial under a non-exclusive

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Medigus and HC Marbella International Hospital Announce Successful First Procedure in Spain

URL: https://investingnews.com/daily/life-science-investing/medical-device-investing/medigus-hc-marbella-international-hospital-announce-successful-first-procedure-spain/